Lakewood-Amedex Biotherapeutics Faces Nasdaq Delisting Over Bid Price Rule

The company has until Nov. 17, 2026 to request a hearing, and plans to ask for one, which would stay the suspension of trading scheduled for Nov. 19.

Stock reaction: LABT shares closed down 2.5% at $0.21 on Nov. 17, from Nov. 16's close of $0.22. The S&P 500 was down 1.0% that day.

science, chemistry, biology, medicine and advertisement concept - close up of scientific laboratory table with stuff
Photo: Ground Picture/Shutterstock.com

Key points

  • Nasdaq says LABT failed the $1.00 bid price rule for 30 business days, Sept. 29 to Nov. 9, 2026
  • A 1-for-10 reverse split on June 22, 2026 rules out a compliance period
  • Trading suspends Nov. 19, 2026 unless the company requests a hearing by Nov. 17
  • Cash and investments of $4.6 million as of June 30, 2026, against a $3.8 million quarterly net loss

Lakewood-Amedex Biotherapeutics Inc. (Nasdaq: LABT) said in an 8-K filed Monday that Nasdaq has determined to delist its common stock because the shares traded below $1.00 for too long.

The company received a letter from Nasdaq's Listing Qualifications Department on Nov. 10, 2026. It said the closing bid price had been below $1.00 for 30 consecutive business days, from Sept. 29, 2026 through Nov. 9, 2026. That is the minimum required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2), which the filing calls the Bid Price Rule.

No grace period this time

Companies that fall short of the Bid Price Rule are often given a compliance period to fix the problem. Lakewood-Amedex is not eligible, the filing says, because it carried out a 1-for-10 reverse stock split on June 22, 2026, within the prior one-year period. Under Nasdaq Listing Rule 5810(c)(3)(A)(iv), that rules out a compliance period, so the staff decided to delist.

The timeline to a hearing

Unless the company requests a hearing by Nov. 17, 2026, trading in its common stock will be suspended at the opening of business on Nov. 19, 2026. Nasdaq would then file a Form 25-NSE with the Securities and Exchange Commission to remove the securities from listing and registration.

The company says it intends to request a hearing before a Nasdaq Hearings Panel. That request would stay the suspension and the Form 25-NSE filing until the panel decides.

Plan before the panel

At the hearing, the company intends to present a plan to regain compliance with the Bid Price Rule. The plan may include another reverse stock split. The filing says there can be no assurance that the panel will grant continued listing or that the company will regain compliance.

Small market value, wider losses

The shares closed at $0.22 on Monday, Nov. 16, 2026, the last close before the filing. Based on about 2.4 million shares as of Aug. 3, 2026, the company's market value was about $0.5 million before the filing. That is a rough figure, since the reverse split cut the share count roughly threefold within a year.

Losses were wider in the latest quarter. For the quarter ended June 30, 2026, the company reported an operating loss and a net loss of $3.8 million, compared with an operating loss of $0.6 million and a net loss of $0.7 million a year earlier. Diluted loss per share was $2.75, against $1.66.

As of June 30, 2026, the company held $2.6 million in cash and equivalents and $2.0 million in short-term investments, or $4.6 million together. The quarter's net loss alone equaled about 83% of that amount. For fiscal 2025, the net loss narrowed to $3.8 million from $4.9 million.

The company did not say in the Nasdaq-related filing how it would fund a hearing plan or any reverse split.

Sources

Written with AI from the company's SEC filing and our market data, and checked against those sources before publishing. Our editorial standards.

LABT page →

Filings, figures and price history are on the Lakewood-Amedex Biotherapeutics page.